AR073586A1 - Compuestos heterociclicos utiles para el tratamiento de vhc - Google Patents

Compuestos heterociclicos utiles para el tratamiento de vhc

Info

Publication number
AR073586A1
AR073586A1 ARP090103513A ARP090103513A AR073586A1 AR 073586 A1 AR073586 A1 AR 073586A1 AR P090103513 A ARP090103513 A AR P090103513A AR P090103513 A ARP090103513 A AR P090103513A AR 073586 A1 AR073586 A1 AR 073586A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
halo
phenyl
cycloalkyl
Prior art date
Application number
ARP090103513A
Other languages
English (en)
Inventor
Andrew Nickel
Louis S Chupak
John F Kadow
Piyasena Hewawasam
Katharine A Grant-Young
Brett R Beno
Ying Han
John A Bender
Kap-Sun Yeung
Kyle E Parcella
Richard Pracitto
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR073586A1 publication Critical patent/AR073586A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Así como composiciones y procedimientos de uso de los compuestos. Los compuestos tienen actividad frente al virus de la hepatitis C (VHC) y pueden ser utiles en el tratamiento de los infectados con el VHC. Reivindicacion 1: Un compuesto caracterizado porque tiene formula (1), (2), (3), (4) o (5) en las que R1 es halo, alquilo cicloalquilo, alcoxi, oxazolidinonilo, dioxotiazinilo, R5R6N, -ciclopropilo-CONR7R8, piperidinonilo sustituido con 1 sustituyente de -C(R9)(R10)(Ar1), pirrolilo sustituido con 1 sustituyente -C(R9)(R10)(Ar1), o fenilo donde dicho fenilo está sustituido con 1- 2 sustituyentes seleccionados del grupo constituido por alquilo, alcoxi, hidroxialquilo, alcoxialquilo, carboxi y CONR7R8, y donde dicho fenilo está también sustituido con 0-2 sustituyentes halo, alquilo, alcoxi, piridinilo, fenilo o halofenilo; R2 es hidrogeno halo, alquilo, cicloalquilo, alcoxi o R5R6N; R3 es ciano, alcoxicarbonilo, (cicloalquil)oxicarbonilo, (alquilsulfonil)aminocarbonilo, CONR11R12, (R13)(R14)NCONH, triazolilo, tiazolilo o tetrazoIilo; R4 es fenilo sustituido con 0-2 halo; R5 es hidrogeno alquilo, cicloalquilo, (cicloalquil)alquilo, bencilo, alquilcarbonilo, haloalquilcarbonilo, fenilcarbonilo, (alcoxifenil)carbonilo, alquilsulfonilo, fenilsulfonilo, (alcoxifenil)sulfonilo o (haloalcoxifenil)sulfonilo, R6 es hidrogeno, alquilo, hidroxialquilo o alcoxialquilo; o R5 y R6 tomados junto con el nitrogeno al que están unidos es oxazolidinonilo o dioxotiazinilo; R7 es hidrogeno alquilo, -C(R9)(R10)(R15) o -C(R9)(R10)(Ar1); R8 es hidrogeno o alquilo; R9 es hidrogeno o alquilo, R10 es hidrogeno o alquilo; o R9 y R10 tomados juntos es etileno, propileno, butileno o pentileno; R11 es hidrogeno o alquilo; R12 es hidrogeno o alquilo, o R11 y R12 tomados junto con el nitrogeno al que están unidos es azetidinilo, pirrolidinilo. piperidinilo, piperazinilo o morfolinilo; R13 es hidrogeno o alquilo; R14 es hidrogeno o alquilo; o R13 y R14 tomados junto con el nitrogeno al que están unidos es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo o morfolinilo; R15 es alquilo o cicloalquilo; R16 es hidrogeno, halo, alquilo o alcoxi; R17 es hidrogeno, halo, alquilo o alcoxi; y Ar1 es isoxazolilo, oxadiazolilo, piridinilo, pirimidinilo o fenilo, y está sustituido con 0-1 sustituyentes halo, alquilo o fenilo; o una de sus sales farmacéuticamente aceptables.
ARP090103513A 2008-09-11 2009-09-11 Compuestos heterociclicos utiles para el tratamiento de vhc AR073586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9600408P 2008-09-11 2008-09-11

Publications (1)

Publication Number Publication Date
AR073586A1 true AR073586A1 (es) 2010-11-17

Family

ID=41203516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103513A AR073586A1 (es) 2008-09-11 2009-09-11 Compuestos heterociclicos utiles para el tratamiento de vhc

Country Status (10)

Country Link
US (2) US8198449B2 (es)
EP (1) EP2331502B1 (es)
JP (1) JP2012502099A (es)
KR (1) KR20110056537A (es)
CN (2) CN103864783A (es)
AR (1) AR073586A1 (es)
AU (1) AU2009291993A1 (es)
MX (1) MX2011002471A (es)
TW (1) TW201014855A (es)
WO (1) WO2010030538A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
CN110483499A (zh) 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
US8324212B2 (en) * 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2545050B1 (en) * 2010-03-10 2014-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
US8324239B2 (en) * 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
NZ610331A (en) * 2010-10-20 2015-01-30 Biota Scient Management Viral polymerase inhibitors
WO2012058125A1 (en) 2010-10-26 2012-05-03 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
EA027418B1 (ru) 2011-06-27 2017-07-31 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2013118097A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013148620A1 (en) 2012-03-27 2013-10-03 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
US9365554B2 (en) 2012-04-11 2016-06-14 Aviragen Therapeutics, Inc. Viral polymerase inhibitors
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
CN102690264B (zh) * 2012-06-20 2014-07-02 泰山医学院 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CN105164124B (zh) 2012-11-19 2017-03-15 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US8962651B2 (en) * 2013-03-13 2015-02-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP3004094B1 (de) 2013-06-04 2017-03-01 Bayer Pharma Aktiengesellschaft 3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
TW201609651A (zh) * 2013-11-12 2016-03-16 陶氏農業科學公司 用於氟化化合物之過程（一）
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト ３−（ピリミジン−２−イル）イミダゾ［１，２−ａ］ピリジン
WO2015143256A1 (en) * 2014-03-21 2015-09-24 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
KR20160126085A (ko) * 2014-03-21 2016-11-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염의 치료를 위한 시아노 함유 아자벤조푸란 화합물
WO2015140199A1 (de) 2014-03-21 2015-09-24 Bayer Pharma Aktiengesellschaft Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
WO2015165930A1 (de) 2014-05-02 2015-11-05 Bayer Pharma Aktiengesellschaft Enantiomere des n-(2-amino-5-fluor-2-methylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-carboxamids sowie der di- and tri-fluor-derivate zur behandlung von kardiovaskulären erkrankungen
EP3180346A1 (en) * 2014-08-05 2017-06-21 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis c
EP3199530A4 (en) 2014-09-26 2017-10-04 Changzhou Yinsheng Pharmaceutical Co., Ltd. Benzofuran analogue as ns4b inhibitor
CA2969268A1 (en) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
EP3328382A4 (en) 2015-09-17 2018-12-19 Marvin J. Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
RU2019123849A (ru) * 2019-07-29 2021-02-01 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Ингибиторы фактора ингибирования миграции макрофагов

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502707A (en) * 1967-09-11 1970-03-24 Mcneilab Inc Beta-(cyclohexyl and substituted phenyl)-alpha-(4,5-dimethoxy-2-nitro- or aminophenyl) acrylonitriles
JPS57123181A (en) 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
EP0595150B1 (de) 1992-10-29 1996-07-31 Hoechst Aktiengesellschaft Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen
CA2315226A1 (en) * 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1372642A1 (en) 2001-03-30 2004-01-02 SmithKline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
CA2484631A1 (en) * 2002-05-13 2003-11-27 Merck & Co., Inc. Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
WO2004041201A2 (en) 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
TW200528459A (en) * 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US20090281120A1 (en) 2005-12-12 2009-11-12 Ono Pharmaceutical Co., Ltd Bicyclic heterocyclic compound
CN101631786A (zh) * 2006-12-20 2010-01-20 先灵公司 新颖的jnk抑制剂
AU2008216382A1 (en) * 2007-02-12 2008-08-21 Array Biopharma, Inc. Novel inhibitors hepatitis C virus replication
JP2008247878A (ja) 2007-03-30 2008-10-16 Maruishi Pharmaceutical Co Ltd イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
KR20100117073A (ko) 2008-02-14 2010-11-02 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
CN103864783A (zh) 2014-06-18
AU2009291993A1 (en) 2010-03-18
US8198449B2 (en) 2012-06-12
CN102209711B (zh) 2014-06-18
JP2012502099A (ja) 2012-01-26
MX2011002471A (es) 2011-04-05
WO2010030538A2 (en) 2010-03-18
CN102209711A (zh) 2011-10-05
EP2331502B1 (en) 2016-03-02
WO2010030538A3 (en) 2010-05-06
US20120232099A1 (en) 2012-09-13
US20100063068A1 (en) 2010-03-11
EP2331502A2 (en) 2011-06-15
KR20110056537A (ko) 2011-05-30
US8536338B2 (en) 2013-09-17
TW201014855A (en) 2010-04-16

Similar Documents

Publication Publication Date Title
AR073586A1 (es) Compuestos heterociclicos utiles para el tratamiento de vhc
AR073740A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR054341A1 (es) Combinaciones sinergicas de compuestos activos fungicidas
AR062928A1 (es) Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
CO5650165A2 (es) Procedimientos para la preparacion de derivados de benzoimidazol
PE20160891A1 (es) Moduladores de ror gamma (rory)
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR061053A1 (es) Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo
ATE512954T1 (de) Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR098147A1 (es) Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico
AR067528A1 (es) Eteres heterociclicos sustituidos y su uso en trastornos del snc
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
AR067542A1 (es) Compuestos macrociclicos de indol utiles para el tratamiento de hepatitis c
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
PE20061316A1 (es) Derivados de pirazol como antagonistas del receptor de progesterona
AR058928A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5. usos y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal